News
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...
If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...
The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...
Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...
Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...
Dr. Celine Gounder joins CBS Mornings to break down the FDA-approved drug Lenacapavir, which is being called the closest step ...
12d
HealthDay on MSNFDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV RiskThe US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.
11don MSN
The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...
9d
News-Medical.Net on MSNTwice-yearly injection could transform HIV prevention effortsPreventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results